Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870198 | 0.85 | NPSR1 (1.00) | ATMNPSR1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL581143 | 0.85 | NPSR1 (1.00) | ATMNPSR1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1931814 | 0.85 | ATM (0.54) | ATMNPSR1ALDH1A1MAPK1MEN1 | |
| SCHEMBL4722654 | 0.84 | ATM (0.66) | ATMNPSR1ALDH1A1MAPK1MEN1 | |
| SCHEMBL30719637 | 0.84 | ATM (0.66) | ATMNPSR1ALDH1A1MAPK1MEN1 | |
| SCHEMBL706420 | 0.82 | ATM (0.73) | ATMNPSR1ALDH1A1MAPK1MEN1 | |
| SCHEMBL31014288 | 0.82 | ATM (0.73) | ATMNPSR1ALDH1A1MAPK1MEN1 | |
| SCHEMBL1904310 | 0.82 | ATM (0.73) | ATMNPSR1ALDH1A1MAPK1MEN1 | |
| SCHEMBL31014290 | 0.82 | ATM (0.73) | ATMNPSR1ALDH1A1MAPK1LMNA | |
| SCHEMBL3710852 | 0.82 | ATM (0.73) | ATMNPSR1ALDH1A1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8747643-B2 | Plating bath and method | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2014-06-10 | — | — | US | claimed |
| US-20140027298-A1 | PLATING BATH AND METHOD | ROHM & HAAS ELECT MAT (US) | 2014-01-30 | — | — | US | claimed |
| US-20130048505-A1 | PLATING BATH AND METHOD | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2013-02-28 | — | — | US | claimed |
| EP-3252049-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150183934-A1 | HIGH TEMPERATURE POLY(ARYL ETHER)S CONTAINING A PHTHALAZINONE MOIETY | POLYMICS, LTD. | 2015-07-02 | — | — | US | disclosed |
| US-8747643-B2 | Plating bath and method | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140027297-A1 | PLATING BATH AND METHOD | ROHM & HAAS ELECT MAT (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140027298-A1 | PLATING BATH AND METHOD | ROHM & HAAS ELECT MAT (US) | 2014-01-30 | — | — | US | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130048505-A1 | PLATING BATH AND METHOD | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7648978-B2 | Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone | ANGION BIOMEDICA CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-0825187-A1 | Condensed pyridazinyl guanidines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
| US-5668279-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DIORDERS AND GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0666851-A4 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS. | — | 1995-08-30 | — | — | EP | disclosed |
| EP-0666851-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010151-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-4824846-A | FUNGICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-25 | — | — | US | disclosed |
| EP-0237963-A2 | 2-Azolylmethyl-2-aryl-1,3-dioxolanes and their salts, processes for their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | HGF, IL2, IL2RA | ATM 2062/4885NPSR1 707/4885ALDH1A1 978/4885 |
| US-20130048505-A1 | PLATING BATH AND METHOD | EPHX1, CYP7B1, AOC3 | ATM 4725/4885NPSR1 3291/4885ALDH1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.